Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Oral White Lesions including Precancers: A Comprehensive Diagnostic Journey

Description

The presentation focuses on oral white lesions, particularly emphasizing oral leukoplakia as a prevalent oral precancer in the U.S. It categorizes these lesions into types based on their characteristics, such as reactive lesions from trauma, immunomediated conditions, infections (like candidiasis), and potentially malignant disorders. Frictional keratosis emerges as a benign condition resulting from trauma, while lichen planus and HPV-related lesions, like squamous papillomas, exemplify other forms of oral lesions. The discussion includes an overview of leukoplakia, outlining its significant risk factors, including tobacco and alcohol use, and the importance of histopathological diagnosis. The presentation also examines treatment strategies, noting that while localized leukoplakia can often be surgically excised, the proliferative type tends to be more challenging due to its higher risk for malignant transformation and possible recurrence. Recent studies explore innovative treatments, including immunotherapy agents like nivolumab and topical therapies like imiquimod, showing varying degrees of success. The conclusion underscores the necessity of biopsies for diagnosis and highlights ongoing research into effective management options for these potentially malignant oral lesions.

View more

Conclusions

  • Oral leukoplakia is the most prevalent oral potentially malignant disorder in the United States.
  • Frictional keratoses and candidiasis are common benign white lesions in the oral cavity.
  • Leukoplakia can present with varying degrees of dysplasia and carries different risks for malignant transformation.
  • Localized leukoplakia has a lower risk of malignant transformation (7% to 22%) compared to proliferative leukoplakia (70% to 100%).
  • Diagnosis of oral leukoplakia should involve a biopsy to assess for dysplasia.
  • Current management strategies for proliferative leukoplakia include potential immunotherapy options such as nivolumab and topical treatment with imiquimod.
  • Complete responses to treatment are possible, but many patients may experience adverse effects.
  • Regular follow-up and monitoring are critical for patients with oral leukoplakia due to the high risk of progression to oral squamous cell carcinoma.
  • Pappas PF et al. Clin Infect Dis. 2016 Feb 15;62(4):e1-50.
  • Bagan J, Johnson NW, Ogden GR. Oral Dis. 2021 Nov;27(8):1862-1880; J Oral Pathol Med. 2007 Nov;36(10):575-80.
  • Villa A et al. Oral Dis. 2018 Mar;24(1-2):179-183.
  • Chaturvedi AK et al. J Natl Cancer Inst. 2020 Oct 1;112(10):1047-1054.
  • Hanna G, Villa A et al. Cancer Research Communications. 2021; 1(1):30-40.
  • Hanna G, Villa A, et al. JAMA Oncol. 2024 Jan 1;10(1):32-41.
  • Alhadlaq MA et al. 2023; 136(5):e160.